Catheter ablation for consecutive atrial tachycardia after AF or heart surgery
Official title: Ablation of CONseCutive atriaL Tachycardia gUided by Ultra-high-DEnsity Mapping
Run by Evangelical Hospital Düsseldorf · NCT05239364 · Data updated 2026-11-12
This trial will test whether a focused, minimal-area catheter ablation guided by ultra-high-density mapping or a standard broader ablation better prevents recurrent atrial tachycardia in people who develop AT after prior atrial fibrillation ablation or cardiac surgery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Evangelical Hospital Düsseldorf Academic / other |
| Locations | 6 sites (Hamburg, Free and Hanseatic City of Hamburg and 5 other locations) |
| Status | Recruiting |
| Started | December 22, 2020 |
| Main results expected | June 2027 |
| Study ends | June 2027 |
| Registry record updated | April 30, 2026 |
| Trial ID | NCT05239364 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with ECG-documented consecutive atrial tachycardia after prior atrial fibrillation ablation or cardiac surgery and with stable, map-able AT (cycle length ≥ 200 ms) are ideal candidates.
✕Probably not a fit
People without prior AF ablation or cardiac surgery, those with unstable or unmappable tachycardia, pregnant women, or patients with contraindications to anticoagulation or significant coagulopathy are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective, multicenter, randomized trial compares a standard ablation strategy to a minimalized ablation that targets only the clinical atrial tachycardia. Ultra-high-density electroanatomical and high-density mapping techniques will be used to characterize AT mechanisms and guide ablation decisions. Eligible adults must have ECG-documented, stable and map-able AT with a cycle length of at least 200 ms following prior AF ablation or cardiac surgery. The primary outcome is arrhythmia-free survival after the randomized ablation approach.
Why it matters
Potential benefit: If successful, the approach could reduce AT recurrences and the need for repeat procedures while limiting the amount of atrial tissue ablated.
How similar studies have gone: Previous observational and non-randomized studies of post-AF or post-surgical AT ablation show mixed results, and ultra-high-density mapping is promising but lacks robust randomized evidence so far.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Consecutive AT subsequent to prior AF ablation procedure or cardiac surgery * Surface ECG-documentation of AT as primary clinical arrhythmia * ECG indicating stable, map-able AT (stable activation sequence, and CL stability) with cycle length ≥ 200ms Exclusion Criteria: * \< 18 years * No previous atrial fibrillation ablation procedure or cardiac surgery * Pregnant women or women of childbearing potential without a negative pregnancy test within 48 hours prior to treatment * History of hemorrhagic diathesis or other coagulopathies * Contraindications for oral anticoagulation * Hyper- or hypothyroidism * Has any condition that would make participation not be in the best interest of the subject
Where it's running
-
Asklepios St. Georg
Hamburg, Free and Hanseatic City of Hamburg, Germany Recruiting -
Evangelic Hospital Düsseldorf
Düsseldorf, North Rhine-Westfalia, Germany Recruiting -
Vivantes Klinikum Am Urban Berlin
Berlin, Germany Recruiting -
Evangelic Hospital Hagen-Haspe
Hagen, Germany Recruiting -
Städtisches Klinikum Karlsruhe
Karlsruhe, Germany Recruiting -
Universitätsklinikum Schleswig Holstein
Kiel, Germany Recruiting
Study contacts
- Principal investigator: Christian Meyer, MD — Evangelic Hospital Düsseldorf
- Study coordinator: Christian Meyer, MD
- Email: christian.meyer@evk-duesseldorf.de
- Phone: 00492119191855
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Heart assessment to check repeat-stroke risk in people with atrial fibrillation
This project will test whether detailed heart examinations can find which people with atrial fibrillation who just had an ischemic stroke are at high risk of having another stroke.
-
Comparing CT and DSA for selecting LAA occluder sizes in heart procedures
This study is testing whether using CT or DSA imaging helps doctors choose the right size of heart device for patients with atrial fibrillation who need a specific procedure.
-
Evaluating different approaches to cardiac pacing in patients
This study is testing different ways to place pacemakers in adults to see which methods work best and are safest for patients needing heart support.
-
Long-term outcomes for patients with cardiac arrhythmias
This study looks at how well treatments for heart rhythm problems work over time and what factors might affect their success for patients with conditions like atrial fibrillation and ventricular tachycardia.
-
Digital healthcare application for cardiac patients
This study tests a digital health app called VIRTUES to see if it can help people with heart conditions manage their health better, especially those living in rural areas without easy access to clinics.
-
Can fluoroscopy plus TTE guidance improve leadless pacemaker placement accuracy
This study tests whether using transthoracic echocardiography (TTE) during leadless pacemaker placement improves accuracy and safety compared with standard fluoroscopy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.